Everolimus tablets 7 — Class III drug recall D-0140-2026
Ongoing recall by Endo USA, Inc., reported 2025-11-05, distributed nationwide. Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
| Recall number | D-0140-2026 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Endo USA, Inc., Malvern, PA, United States |
| Recall initiated | 2025-10-10 |
| Classified | 2025-10-29 |
| Reported by FDA | 2025-11-05 |
| Distributed | Nationwide (US) |
| Quantity | 1,866 cartons |
| Reason classes | specification failure |
| NDC | 49884-0127-91 |
| Lot numbers | 550167301, 550167401, 550185101, 550205701, JUL-26, MAR-26, NOV-25 |
Product
Everolimus tablets 7.5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-127-91
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0140-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.